Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1989-02-27
1990-09-18
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540509, C07D24314, A61K 3155
Patent
active
049579150
ABSTRACT:
BZDs of the general formula 1: ##STR1## where: R represents H, alkyl, alkenyl, cycloalkyl or cycloalkenyl each with up to 8 carbon atoms, phenylalkyl with an alkylene chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substituents selected from the group consisting of Cl, Br, F, CN, CF.sub.3, NO.sub.2, lower alkyl, and OCH.sub.3, or represents a phenyl radical which is optionally substituted with one or two substituents selected from the group consisting of Cl, F, Br, CN, I, CF.sub.3 NO.sub.2, lower alkyl and OCH.sub.3, or represents a 5-membered or 6-membered heterocyclic radical with 1 or 2 heteroatoms from the group consisting of O, N and S; R.sub.1 represents H or, together with R.sub.2, forms a bond; R.sub.2 and R.sub.4 independently of one another represent H, or an alkyl radical with 1 to 6 carbon atoms, or represent a phenylalkyl radical with an alkyl chain of 1 to 3 carbon atoms and optionally substituted on the phenyl radical with one or two substituents selected from the group consisting of Cl, Br, F, CN, CF.sub.3, NO.sub.2, CH.sub.3, C.sub.2 H.sub.5 and OCH.sub.3, or R.sub.2 together with R.sub.1, forms a bond; R.sub.3 is (CH.sub.2).sub.n CH or (CH.sub.2).sub.n --CR.sub.14 .dbd.CR.sub.14, where n is between 0 and 5 inclusive and R.sub.14 .dbd.HOL a bond; R.sub.5 and R.sub.6 independently of one another represent H, Cl, F, Br, NO.sub.2, CN, CF.sub.3, lower alkyl, or OCH.sub.3 ; R.sub.7 and R.sub.9 are independently CH.sub.2 or C.dbd.0; R.sub.8 is ##STR2## where p and q are independently between 0 and 4 and the sum of p and q is 4 or less; and R.sub.11 and R.sub.12 are independently H or a lower alkyl of between 1 and 5 carbon atoms.
REFERENCES:
patent: 4631285 (1986-12-01), Petersen et al.
patent: 4647560 (1987-03-01), Boltz et al.
patent: 4738973 (1988-04-01), Gittos
Kulkarni et al., "Synthesis of 3-Substituted-amino/aroyloxy-7-chloro-5-phenyl 1,3 dihydro-2H-1,4-benzodiazepine-2-ones as Possible Anxiolytics" J. Indian Chem. Soc., vol. LXIII, pp. 425-426.
Colotta et al., "Synthesis, Binding Studies, and Structure-Activity Relationships of 1-Aryl- and 2-Aryl[1]benzopyranopyrazol-4-ones, Central Benzodiazepine Receptor Ligands", J. Medicinal Chem., vol. 31, No. 1, Jan. 1988.
Yokoyama et al., "2-Arylpyrazolo[4,3-c]quinolin-3-ones: Novel Agonist, Partial Agonist, and Antagonist of Benzodiazepines", J. Medicinal Chem., vol. 25, No. 4, pp. 337-339, 1982.
Trudell et al., "Synthesis of 7,12-Dihydropyrido[3,4-b:5,4-b']diindoles, A Novel Class of Rigid, Planar Benzodiazepine Receptor Ligands," J. Medicinal Chem., vol. 30, No. 3, pp. 456-458, 1987.
Takada et al., "A New Thienylpyrazoloquinoline: A Potent and Orally Active Inverse Agonist to Benzodiazepine Receptors," J. Medicinal Chem., vol. 30, No. 3, pp. 454-455, 1987.
Lister, "The Benzodiazepine Receptor Inverse Agonists FG 7142 and RO 15-4513 Both Reverse Some of the Behavioral Effects of Ethanol in Holeboard Test," Life Sciences, vol. 41, No. 12, pp. 1481-1489, 1987.
Braestrup et al., "Urinary and brain .beta.-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors," Proc. Nat. Acad. Sci. U.S.A., vol. 77, No. 4, pp. 2288-2292, Apr. 1980.
Mohler et al., "Photoaffinity Labeling of Benzodiazepine Receptors with a Partial Inverse Agonist," European Journal of Pharmacology, vol. 102, pp. 191-192, 1984.
Polc et al., "A Three-State Model of the Benzodiazepine Receptor Explains the Interactions Between the Benzodiazepine Antagonist Ro 15-1788, Benzodiazepine Tranquilizers, .beta.-Carbolines, and Phenobarbitone," Naunyn-Schmiedeberg's Arch. Pharmacol., vol. 321, No. 4, pp. 260-264, 1982.
Trullas et al., "3-Ethoxy-.beta.-Carboline: A High Affinity Bezodiazepine Receptor Ligand with Partial Inverse Agonist Properties," Life Sciences, vol. 43, No. 15, pp. 1189-1197, 1988.
Sarter et al., "Treatment strategies for senile dementia: antagonist .beta.-carbolies," TINS, vol. 11, No. 1, pp. 13-17, 1988.
Lavie, "RO 15-1788 Decreases Hypnotic Effects of Sleep Deprivation," Life Sciences, vol. 41, No. 2, pp. 227-233, 1987.
Venault et al., "Benzodiazepine impairs and .beta.-carboiine enhances performance in learning and memory tasks," Nature, Vo. 321, pp. 864-866, Jun. 26, 1986.
Lal et al., "Enhancement of learning and memory in mice by a benzodiazepine antagonist," The FASEB Journal, vol. 2, No. 11, pp. 2707-2711, Aug. 1988.
Kemp et al., "The affinities, potencies and efficacies of some benzodiazepine-receptor agonists, antagonists and inverse-agonists at rat hippocampal GABA.sub.A -receptors," Br. J. Pharmac., vol. 91, No. 3, pp. 601-608, Jul. 1987.
Nutt, "Benzodiazepine dependence in the clinic: reason for anxiety," TIPS, vol. 7, pp. 457-460, Nov. 1986.
Squires and Braestrup, "Benzodiazepine receptors in rat brain," Nature, vol. 266, pp. 732-734, Apr. 21, 1977.
Lader, "Benzodiazepines--The Opium of the Masses?", Neuroscience, vol. 3, No. 2, pp. 159-165, Feb. 1978.
Hunkeler et al., "Selective antagonists of benzodiazepines,"Nature, vol. 290, pp. 514-516, Apr. 9, 1981.
Freidinger et al., "Design of Novel Antagonists of Cholecystokynin," Topics in Medicinal Chemistry, 4th SCI-RSC Medicinal Chemistry Symposium, Ed. by P. R. Leeming, Royal Society of Chemistry, 1988.
Kim Sun H.
Taylor John E.
Biomeasure Inc.
Bond Robert T.
LandOfFree
Benzodiazepine analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzodiazepine analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzodiazepine analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1572798